Aug 16, 2016 - TORNTO - Genesys Capital has collected almost three-quarters of the $125 million target set for its third venture fund, adding to the momentum felt of late in Canada’s life-sciences sector.

Genesys Ventures III initially closed at $90 million in committed capital, the Toronto firm said today. It is expected to reach its goal early next year, Managing Director Damian Lamb told PE Hub Canada. 

Should the fund reach its $125 million target, it will be the largest Genesys has raised in its 16-year history.

For the full article, click here

August 15, 2016 Tissue Regeneration Therapeutics Inc. (TRT) today announced that a team of Canadian researchers has for the first time shown that TRT’s engineered mesenchymal stromal cell product (eTXP) can be used to deliver therapeutically useful monoclonal antibodies (mAbs) more effectively than administration of the mAbs themselves. The study appears this month, as a featured paper, in the journal STEM CELLS Translational Medicine.

For the full release click here

Aug 12, 2016 TORONTO - Spectral Medical Inc., (TSX:EDT) (OTCQX:EDTXF), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the second quarter ended June 30, 2016.

Spectral is a Phase III company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ ('PMX"). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis, Spectral's EUPHRATES trial is the world's only active and most innovative Phase III study in the area of septic shock.

For the full press release, click here

August 3, 2016, London Ontario – The Centre for Imaging Technology Commercialization (CIMTEC) is pleased to announce the appointment of Greg Hood as Chief Executive Officer, effective immediately.

July 5, 2016 TORONTO – Synaptive Medical Inc., a company focused on global commercialization of innovative solutions, announced the approval from Health Canada to market BrightMatterTM Guide. This new technology is part of a solution for health care providers that includes informatics, imaging, surgical planning, navigation and advanced optics.

July 4, 2016, TORONTO - Ontario's $20 million Health Technologies Fund (HTF) is open for business.

Announced in May by William Charnetski, Ontario's Chief Health Innovation Strategist, the Fund will support the development of leading, market-ready, made-in-Ontario health technologies by accelerating prototyping, evaluation, adoption and diffusion in the Ontario health care sector.

June 29, 2016, London ON – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is increasing its non-brokered private placement to $4,200,000, equal to 16,800,000 units (the “Units”) at $0.25 per Unit, to accommodate additional over-subscriptions (see news releases dated June 27, 2016 and June 21, 2016 for further information about the private placement).

June 27, 2016 LONDON, ONTARIO Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it is closing today $2,000,000 of its non-brokered private placement announced on June 21, 2016. In addition, as the Company has received over-subscriptions of $1,650,000, it is increasing the total amount of the non-brokered private placement offering to $3,750,000 for a total offering of 15,000,000 units (the “Units”) at $0.25 per Unit. The Company plans to close the balance of the placement, Thursday, June 30th, 2016.

June 21, 2016 LONDON, ONTARIO – Sernova Corp. (“Sernova” or the “Company”) (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH) announced today that it has arranged a non-brokered private placement for gross proceeds of $2,000,000. The private placement consists of 8,000,000 units (the “Units”) at a price of $0.25 per Unit.

Canadian Manufacturers & Exporters congratulates Valeant Canada on its $27.5 million commitment to expand manufacturing operations in Canada.

For the full article click here

Berlin, Germany, and Toronto, Canada, MAY 24, 2016: SCIENION AG, a developer of a revolutionary new ultra-low volume liquid handling technology, is pleased to announce that it has entered into a strategic, joint development agreement with AXELA Inc.

For the full press release, click here

Asthma Society of Canada invites you to register for the Fighting for Breath: Severe Asthma Conference

March 3, 2016 QoC Health is a technology partner on McMaster University’s SMArTVIEW project. The $12.3 million project has recently received a $750,000 grant from the eHealth Innovation Partnership Program (eHIPP) from Canadian Institutes of Health Research (CIHR).

March 2, 2016 Today, the Globe and Mail Report on Business published an op-ed penned by NACO's Co-Chairs, Ian Bandeen and Bev Tudhop. Titled, "For a Fraction of the Price, Angel Investors Can Pay Huge Dividends".

Grace Soyao, Founder & CEO, Self Care Catalysts Inc. writes about "Creating Breakthroughs in Entreprneurship" in 4 key steps.

Click here for the full article 

TORONTO, Canada, February 9, 2016 - Interface Biologics Inc. (IBI) is pleased to announce that Fresenius Medical Care, the worlds’ largest integrated provider of dialysis products and services, has extended their exclusive licensing agreement for use of Endexo™ technology in chronic dialysis systems to cover the acute dialysis market (including CRRT).